Real-Time MRI-Guided Stereotactic Body Radiation Therapy and Microwave Ablation in Treating Patients with Kidney Cancer that Cannot Be Removed by Surgery

This phase IA/IB trial studies the side effects and best dose of real-time magnetic resonance imaging (MRI)-guided stereotactic body radiation therapy when given together with microwave ablation in patients with kidney cancer that cannot be removed by surgery. Diagnostic procedures, such as real-time MRI, allow for doctors to directly see tumors and track their motion during radiation therapy and may help plan the best treatment for kidney cancer. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Microwave ablation may kill tumor cells by heating them to several degrees above normal body temperature. Giving real-time MRI-guided stereotactic body radiation therapy together with microwave ablation may work better in treating patients with kidney cancer that cannot be removed by surgery.

Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT02782715.

Trial PhasePhase I

Trial Typetreatment

Lead OrganizationUniversity of Wisconsin Carbone Cancer Center - University Hospital

Principal InvestigatorMichael F. Bassetti

• Primary IDUW15103
• Secondary IDsNCI-2016-00775, 2016-0286
• ClinicalTrials.gov IDNCT02782715